The article examines the limitations of traditional, protocol-driven cancer treatment and explains how AI-driven Functional Precision Medicine (FPM) is transforming how oncologists select therapies. It outlines how combining patient-derived tumor biology with automation, robotics, and artificial intelligence allows clinicians to test how an individual patient’s cancer responds to hundreds of FDA-approved drugs and combinations in a matter of days.